Sanofi S.A. operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Sanofi S.A. with three other
pharmaceutical manufacturers in Europe:
Bayer AG
of GERMANY
(2020
sales of 41.40 billion Euros [US$48.03 billion]
of which 46%
was CropScience),
GlaxoSmithKline plc
of UNITED KINGDOM
(£34.10 billion [US$46.90 billion]
of which 50%
was Pharmaceuticals), and
Novartis AG
which is
based in SWITZERLAND
(46.58 billion Swiss Francs [US$50.46 billion]
of which 78%
was Innovative Medicines).
Sales Analysis.
During the second
quarter of 2021, sales at Sanofi S.A. totalled
9.05 billion Euro.
This is
an increase of 7.2%
from the 8.44 billion Euro in sales at the company during the second quarter of 2020.
During the first two
quarters of 2021, sales totalled 17.93 billion Euro, which is
1.0% higher
than through the first two quarters of 2020.
During the year ended December of 2020, sales at
Sanofi S.A. were 37.37 billion Euro (US$43.35 billion).
This
is
a
decrease of 0.7%
versus 2019, when the company's sales were 37.63 billion Euro.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Sanofi S.A. had sales
of 34.86 billion Euro.
Contributing to the drop in overall sales was the 6.3% decline
in Consumer Healthcare, from 4.69 billion Euro to 4.39 billion Euro.
There were also decreases in sales in
Pharmaceuticals (down 0.1% to 25.67 billion Euro)
.
However, these declines were partially offset by the increase in sales of
Vaccines (up 4.2% to 5.97 billion Euro)
.